Pub Date : 2021-06-01Epub Date: 2020-09-16DOI: 10.15761/jts.1000421
H Akkiz, B I Carr, V Guerra, R Donghia, K Yalçın, U Karaoğullarından, E Altıntaş, A Özakyol, H Şimşek, H Y Balaban, A Balkan, A Uyanıkoğlu, N Ekin, A Delik
Introduction and aims: Hepatocellular carcinoma (HCC) is a consequence of chronic liver disease, particularly from hepatitis B or C and increasingly from obesity and metabolic syndrome. Since lipids are an important component of cell membranes and are involved in cell signaling and tumor cell growth, we wished to evaluate the relationship between HCC patient plasma lipids and maximum tumor diameter and other indices of HCC human biology.
Methods: We examined prospectively-collected data from a multi-institutional collaborative Turkish HCC working group, from predominantly HBV-based patients, for plasma lipid profiles, consisting of triglycerides, total cholesterol, LDL-cholesterol (LDL) and HDL-cholesterol (HDL) and compared these with the associated patient maximum tumor diameter (MTD), portal vein thrombosis, alpha-fetoprotein (AFP) and also with patient survival.
Results: We found that both low HDL (p=0.0002) and high LDL (p=0.003) levels were significantly associated with increased MTD, as well as in a final multiple linear regression model on MTD. The combination of low HDL combined with high HDL levels were significant in a regression model on MTD, PVT and an HCC Aggressiveness Index (Odds Ratio 12.91 compared to an Odds Ratio of 1 for the reference). Furthermore, in a Cox regression model on death, the HDL plus LDL combination had a significantly higher Hazard Ratio than the reference category.
Conclusions: Low plasma HDL, high plasma LDL and especially the combination, were significantly related to more aggressive HCC phenotype and the combination was significantly related to a higher Hazard Ratio for death.
{"title":"Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV.","authors":"H Akkiz, B I Carr, V Guerra, R Donghia, K Yalçın, U Karaoğullarından, E Altıntaş, A Özakyol, H Şimşek, H Y Balaban, A Balkan, A Uyanıkoğlu, N Ekin, A Delik","doi":"10.15761/jts.1000421","DOIUrl":"10.15761/jts.1000421","url":null,"abstract":"<p><strong>Introduction and aims: </strong>Hepatocellular carcinoma (HCC) is a consequence of chronic liver disease, particularly from hepatitis B or C and increasingly from obesity and metabolic syndrome. Since lipids are an important component of cell membranes and are involved in cell signaling and tumor cell growth, we wished to evaluate the relationship between HCC patient plasma lipids and maximum tumor diameter and other indices of HCC human biology.</p><p><strong>Methods: </strong>We examined prospectively-collected data from a multi-institutional collaborative Turkish HCC working group, from predominantly HBV-based patients, for plasma lipid profiles, consisting of triglycerides, total cholesterol, LDL-cholesterol (LDL) and HDL-cholesterol (HDL) and compared these with the associated patient maximum tumor diameter (MTD), portal vein thrombosis, alpha-fetoprotein (AFP) and also with patient survival.</p><p><strong>Results: </strong>We found that both low HDL (p=0.0002) and high LDL (p=0.003) levels were significantly associated with increased MTD, as well as in a final multiple linear regression model on MTD. The combination of low HDL combined with high HDL levels were significant in a regression model on MTD, PVT and an HCC Aggressiveness Index (Odds Ratio 12.91 compared to an Odds Ratio of 1 for the reference). Furthermore, in a Cox regression model on death, the HDL plus LDL combination had a significantly higher Hazard Ratio than the reference category.</p><p><strong>Conclusions: </strong>Low plasma HDL, high plasma LDL and especially the combination, were significantly related to more aggressive HCC phenotype and the combination was significantly related to a higher Hazard Ratio for death.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"7 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39364769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01Epub Date: 2020-09-17DOI: 10.15761/jts.1000446
B I Carr, H Akkiz, H G Bag, U Karaoğullarından, K Yalçın, N Ekin, A Özakyol, E Altıntaş, H Y Balaban, H Şimşek, A Uyanıkoğlu, A Balkan, S Kuran, O Üsküdar, Y Ülger, B Güney, A Delik
Background and aim: Hepatocellular carcinoma (HCC) biomarkers are limited, as even the best studied, alpha-fetoprotein (AFP), is elevated in no more than 50% of HCC patients. The aim was to evaluate several serum liver function tests in relation to survival and tumor characteristics in a large cohort of Turkish HCC patients.
Methods: We retrospectively examined the serum levels of gamma glutamyl transpeptidase (GGT) in relation to patient survival.
Results: Kaplan-Meier analysis showed that only GGT and albumin amongst liver function tests, were significantly associated with survival. Survival worsened with increase in GGT levels semi-quantitatively. Increase in GGT levels was also found to significantly correlate with an increase in maximum tumor diameter from 4.5 to 7 cm, a 20-fold increase in serum alpha-fetoprotein level, an increase in tumor multifocality from 20 to 54% of patients, and a doubling in percent of patients with portal vein thrombosis (PVT) from 20 to 40%. Serum GGT levels also showed significant survival differences for patients with low AFP levels. A doublet combination of serum GGT with albumin levels was associated with higher hazard ratios in a Cox regression analysis, as compared with single parameter GGT. The combination parameter pair was also prognostically useful in the low-AFP patient subcohort and was associated with significant differences in patient tumor characteristics.
Conclusions: Serum GGT levels and especially combination serum GGT plus albumin levels, were significantly associated both with HCC patient survival and tumor aggressiveness characteristics, regardless of AFP levels in a large Turkish cohort. This might be especially useful since the majority of HCC patients do not have elevated levels of AFP.
{"title":"Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis.","authors":"B I Carr, H Akkiz, H G Bag, U Karaoğullarından, K Yalçın, N Ekin, A Özakyol, E Altıntaş, H Y Balaban, H Şimşek, A Uyanıkoğlu, A Balkan, S Kuran, O Üsküdar, Y Ülger, B Güney, A Delik","doi":"10.15761/jts.1000446","DOIUrl":"https://doi.org/10.15761/jts.1000446","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatocellular carcinoma (HCC) biomarkers are limited, as even the best studied, alpha-fetoprotein (AFP), is elevated in no more than 50% of HCC patients. The aim was to evaluate several serum liver function tests in relation to survival and tumor characteristics in a large cohort of Turkish HCC patients.</p><p><strong>Methods: </strong>We retrospectively examined the serum levels of gamma glutamyl transpeptidase (GGT) in relation to patient survival.</p><p><strong>Results: </strong>Kaplan-Meier analysis showed that only GGT and albumin amongst liver function tests, were significantly associated with survival. Survival worsened with increase in GGT levels semi-quantitatively. Increase in GGT levels was also found to significantly correlate with an increase in maximum tumor diameter from 4.5 to 7 cm, a 20-fold increase in serum alpha-fetoprotein level, an increase in tumor multifocality from 20 to 54% of patients, and a doubling in percent of patients with portal vein thrombosis (PVT) from 20 to 40%. Serum GGT levels also showed significant survival differences for patients with low AFP levels. A doublet combination of serum GGT with albumin levels was associated with higher hazard ratios in a Cox regression analysis, as compared with single parameter GGT. The combination parameter pair was also prognostically useful in the low-AFP patient subcohort and was associated with significant differences in patient tumor characteristics.</p><p><strong>Conclusions: </strong>Serum GGT levels and especially combination serum GGT plus albumin levels, were significantly associated both with HCC patient survival and tumor aggressiveness characteristics, regardless of AFP levels in a large Turkish cohort. This might be especially useful since the majority of HCC patients do not have elevated levels of AFP.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"7 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39430651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-01Epub Date: 2021-06-16DOI: 10.15761/jts.1000458
Jenna Klug, Sara Christensen, Denise M Imai, Timothy A Snider, Warren Ladiges
Aging is a complex multidimensional process of progressive decline affecting multiple organ systems by a number of processes that are still not well understood. While many studies have focused on the approach of studying aging across multiple organs, assessment of the contribution of individual organs to overall aging processes is under appreciated. The ability to study and compare organs in the context of organismal aging has been documented recently using a geropathology grading platform in laboratory mice. This concept consists of identifying and grading age-related histologic lesions within organs to generate a quantitative lesion score for each organ, which is representative of the presence and degree of organ-related pathology, and can be compared to scores from other organs examined. This geropathology approach provides a powerful tool to elucidate the basic mechanisms of aging in multiple organs, as well as the response of organs to therapeutic interventions. Furthermore, ongoing work with the concept has expanded and adapted the geropathology grading system to other preclinical animal model species that are commonly used to understand disease associated phenotypes in aging humans, ultimately adding to the utility of the concept.
{"title":"The geropathology of organ-specific aging.","authors":"Jenna Klug, Sara Christensen, Denise M Imai, Timothy A Snider, Warren Ladiges","doi":"10.15761/jts.1000458","DOIUrl":"10.15761/jts.1000458","url":null,"abstract":"<p><p>Aging is a complex multidimensional process of progressive decline affecting multiple organ systems by a number of processes that are still not well understood. While many studies have focused on the approach of studying aging across multiple organs, assessment of the contribution of individual organs to overall aging processes is under appreciated. The ability to study and compare organs in the context of organismal aging has been documented recently using a geropathology grading platform in laboratory mice. This concept consists of identifying and grading age-related histologic lesions within organs to generate a quantitative lesion score for each organ, which is representative of the presence and degree of organ-related pathology, and can be compared to scores from other organs examined. This geropathology approach provides a powerful tool to elucidate the basic mechanisms of aging in multiple organs, as well as the response of organs to therapeutic interventions. Furthermore, ongoing work with the concept has expanded and adapted the geropathology grading system to other preclinical animal model species that are commonly used to understand disease associated phenotypes in aging humans, ultimately adding to the utility of the concept.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10755956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-01Epub Date: 2020-06-16DOI: 10.15761/jts.1000431
Stephanie A Eid, Phillipe D O'Brien, Lucy M Hinder, John M Hayes, Faye E Mendelson, Hongyu Zhang, Samanthi Narayanan, Steven F Abcouwer, Frank C Brosius, Subramaniam Pennathur, Masha G Savelieff, Eva L Feldman
Diabetes is a global healthcare problem associated with enormous healthcare and personal costs. Despite glucose lowering agents that control glycaemia, both type 1 (T1D) and type (T2D) diabetes patients often develop microvascular complications that increase morbidity and mortality. Current interventions rely on careful glycemic control and healthy lifestyle choices, but these are ineffective at reversing or completely preventing the major microvascular complications, diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), and diabetic kidney disease (DKD). Minocycline, a tetracycline antibiotic with anti-inflammatory and anti-apoptotic properties, has been proposed as a protective agent in diabetes. However, there are no reported studies evaluating the therapeutic efficacy of minocycline in T1D and T2D models for all microvascular complications (DPN, DR, and DKD). Therefore, we performed metabolic profiling in streptozotocin-induced T1D and db/db T2D models and compared the efficacy of minocycline in preventing complications to that of insulin and pioglitazone in both models. Minocycline partially ameliorated DR and DKD in T1D and T2D animals, but was less effective than insulin or pioglitazone, and failed to improve DPN in either model. These results suggest that minocycline is unlikely to improve outcomes beyond that achieved with current available therapies in patients with T1D or T2D associated microvascular complications.
{"title":"Differential effects of minocycline on microvascular complications in murine models of type 1 and type 2 diabetes.","authors":"Stephanie A Eid, Phillipe D O'Brien, Lucy M Hinder, John M Hayes, Faye E Mendelson, Hongyu Zhang, Samanthi Narayanan, Steven F Abcouwer, Frank C Brosius, Subramaniam Pennathur, Masha G Savelieff, Eva L Feldman","doi":"10.15761/jts.1000431","DOIUrl":"https://doi.org/10.15761/jts.1000431","url":null,"abstract":"<p><p>Diabetes is a global healthcare problem associated with enormous healthcare and personal costs. Despite glucose lowering agents that control glycaemia, both type 1 (T1D) and type (T2D) diabetes patients often develop microvascular complications that increase morbidity and mortality. Current interventions rely on careful glycemic control and healthy lifestyle choices, but these are ineffective at reversing or completely preventing the major microvascular complications, diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), and diabetic kidney disease (DKD). Minocycline, a tetracycline antibiotic with anti-inflammatory and anti-apoptotic properties, has been proposed as a protective agent in diabetes. However, there are no reported studies evaluating the therapeutic efficacy of minocycline in T1D and T2D models for all microvascular complications (DPN, DR, and DKD). Therefore, we performed metabolic profiling in streptozotocin-induced T1D and db/db T2D models and compared the efficacy of minocycline in preventing complications to that of insulin and pioglitazone in both models. Minocycline partially ameliorated DR and DKD in T1D and T2D animals, but was less effective than insulin or pioglitazone, and failed to improve DPN in either model. These results suggest that minocycline is unlikely to improve outcomes beyond that achieved with current available therapies in patients with T1D or T2D associated microvascular complications.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38886433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wong Lx, Wong Jc, B. Chee, Bloom Gm, Sharma Mj, G. Liang, Park Jm
1Department of Clinical Research and Leadership, The George Washington University, School of Medicine and Health Sciences, USA 2Department of Hematology and Oncology, Gastrointestinal Oncology, University of California, San Francisco, USA 3Department of Nursing, University of San Francisco School of Nursing and Health Professions, USA 4Department of Primary Care, Touro University College of Osteopathic Medicine – California, USA 5Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, Interstitial Lung Disease, University of California, San Francisco, USA 6Department of Law, Santa Clara University School of Law, USA 7Department of Medical Education, Rush University Medical College, USA
{"title":"Conducting a pre-consent process for clinical trials: Promoting a more-true informed consent","authors":"Wong Lx, Wong Jc, B. Chee, Bloom Gm, Sharma Mj, G. Liang, Park Jm","doi":"10.15761/jts.1000415","DOIUrl":"https://doi.org/10.15761/jts.1000415","url":null,"abstract":"1Department of Clinical Research and Leadership, The George Washington University, School of Medicine and Health Sciences, USA 2Department of Hematology and Oncology, Gastrointestinal Oncology, University of California, San Francisco, USA 3Department of Nursing, University of San Francisco School of Nursing and Health Professions, USA 4Department of Primary Care, Touro University College of Osteopathic Medicine – California, USA 5Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, Interstitial Lung Disease, University of California, San Francisco, USA 6Department of Law, Santa Clara University School of Law, USA 7Department of Medical Education, Rush University Medical College, USA","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67492485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical features of stercoral perforation of colon compared with perforated colon diverticulum: A single center experience","authors":"Takahiro Murakami, Morihiro Katsura, Masafumi Ie, Takashi Kato","doi":"10.15761/jts.1000441","DOIUrl":"https://doi.org/10.15761/jts.1000441","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"165 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67493133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dennis R.A. Mans, M. Djotaroeno, J. Pawirodihardjo, P. Friperson
{"title":"Exploring the global animal biodiversity in the search for new drugs - Reptiles","authors":"Dennis R.A. Mans, M. Djotaroeno, J. Pawirodihardjo, P. Friperson","doi":"10.15761/jts.1000457","DOIUrl":"https://doi.org/10.15761/jts.1000457","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67499105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The occurrence of antibody dependent enhancement (ADE) in SARS-CoV-2 infection: implications for treatment","authors":"M. Guastalegname, Laura D’argenio, A. Vallone","doi":"10.15761/jts.1000449","DOIUrl":"https://doi.org/10.15761/jts.1000449","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67499516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Styliani Paliatsiou, T. Boutsikou, T. Xanthos, Paraskevi Volak, R. Sokou, Z. Iliodromiti, N. Iacovidou
{"title":"Stress in healthcare personnel involved in neonatal resuscitation – A systematic review","authors":"Styliani Paliatsiou, T. Boutsikou, T. Xanthos, Paraskevi Volak, R. Sokou, Z. Iliodromiti, N. Iacovidou","doi":"10.15761/jts.1000447","DOIUrl":"https://doi.org/10.15761/jts.1000447","url":null,"abstract":"","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67498239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wong Am, Baik Je, H. Park, C. Li, Shi Jy, Kataru Rp, Mehrara Bj
Introduction: Recent studies have shown that taxanes — chemotherapeutic agents commonly used for breast cancer treatment—may increase the risk of lymphedema development in breast cancer survivors. The purpose of this study was to analyze the effects of docetaxel on lymphatic endothelial cells (LEC) and define the cellular mechanisms that may account for this clinical relationship. Methods: Human dermal LECs were cultured in vitro with varying concentrations of docetaxel and LEC viability, proliferation, migration, tubule formation and lymphatic gene expression were analyzed. Results: Docetaxel, at a concentration of 100 µM, was cytotoxic to LECs resulting in impaired proliferation. At the lower concentrations (1 and 10 µM), docetaxel impaired LEC function by decreasing LEC migration and tubule formation. The expression of lymphatic markers podoplanin, LYVE1 and FLT4, but not PROX-1 were down-regulated in LECs following high concentration of docetaxel treatment (100 µM). Conclusion: High concentration of docetaxel induces LEC death and impair LEC proliferation and lymphatic gene expression. In contrast, low concentration of docetaxel significantly impairs LEC migration and tubule formation. These adverse effects of docetaxel may therefore provide a cellular mechanism underlying the clinical observation that taxane therapy increases the risk of lymphedema development in cancer patients.
{"title":"Docetaxel causes lymphatic endothelial cell apoptosis and impairs lymphatic function and gene expression in vitro","authors":"Wong Am, Baik Je, H. Park, C. Li, Shi Jy, Kataru Rp, Mehrara Bj","doi":"10.15761/jts.1000402","DOIUrl":"https://doi.org/10.15761/jts.1000402","url":null,"abstract":"Introduction: Recent studies have shown that taxanes — chemotherapeutic agents commonly used for breast cancer treatment—may increase the risk of lymphedema development in breast cancer survivors. The purpose of this study was to analyze the effects of docetaxel on lymphatic endothelial cells (LEC) and define the cellular mechanisms that may account for this clinical relationship. Methods: Human dermal LECs were cultured in vitro with varying concentrations of docetaxel and LEC viability, proliferation, migration, tubule formation and lymphatic gene expression were analyzed. Results: Docetaxel, at a concentration of 100 µM, was cytotoxic to LECs resulting in impaired proliferation. At the lower concentrations (1 and 10 µM), docetaxel impaired LEC function by decreasing LEC migration and tubule formation. The expression of lymphatic markers podoplanin, LYVE1 and FLT4, but not PROX-1 were down-regulated in LECs following high concentration of docetaxel treatment (100 µM). Conclusion: High concentration of docetaxel induces LEC death and impair LEC proliferation and lymphatic gene expression. In contrast, low concentration of docetaxel significantly impairs LEC migration and tubule formation. These adverse effects of docetaxel may therefore provide a cellular mechanism underlying the clinical observation that taxane therapy increases the risk of lymphedema development in cancer patients.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67491806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}